Express Pharma

Sipra Labs records 30 per cent growth in 2012-13

0 288

Sipra Labs has announced a 30 per cent growth in 2012-13, and has now set sights on achieving a target of Rs 100 crores in the next 4-5 years. The last financial year turnover was Rs 33 crores. “If we follow the same growth path we will achieve it without much difficulty,” says K Sreedhar, Director (Analytical).

Sipra specialises in crystallography studies, metabolic studies, genotoxity, and impurity profile. “We have now attained the reputation of being a one-stop research and solution provider to the industry. We not only help organisations by testing their product samples but also help them in filing for clearances from USFDA and other regulatory organisations by providing detailed analysis. Sipra has complete expertise in testing for genetoxic impurities,’’ Sreedhar says.

Sipra is also reportedly working on providing web-enabled, post-analytical services. “Customers will want to access research and analytical records from time to time and we want to put it up online for them. For this we are creating a database here and records of all our customers will be available to them at the click of the mouse. It is a very quick response mechanism, especially very helpful during audits etc,” informed Sreedhar.

Talking about the industry’s growth, he said that it is an emerging sector and testing requirements will only go up due to tighter regulations and thus the industry has a good future.

EP News BureauMumbai

Leave A Reply

Your email address will not be published.